Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1993-04-30
1999-08-10
Sayala, Chhaya D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
424449, 514282, 514286, 514561, 514947, 514660, 514810, 514812, 514813, 514922, A61K 3144, A61K 970
Patent
active
059359757
ABSTRACT:
A method of treating and reducing a drug dependency such as a nicotine dependency is provided. The method comprises initially administering to a subject a drug, such as nicotine or an agonist of the drug in an amount which would normally provide the desired pharmacologic effects and at least partially satiate the needs for the drug by a user. The method also comprises administering to the subject an antagonist to the drug or an agonist in an amount sufficient to at least partially block the pharmacologic effects of the drug or an agonist while there is a substantial amount of the drug or an agonist present in the system of the user. In one embodiment of the invention, the drug and the antagonist are administered substantially simultaneously so as to occupy a substantial portion of the receptors of the user for that drug thereby blocking or attenuating the effects of any further intake of the drug or an agonist thereof. In another embodiment, the drug or an agonist is first administered and the antagonist is self-administered by a subject in a manner which mimics the use of the drug thereby counter-conditioning the drug user to the stimuli associated with the normal administration of the drug. The invention further provides a method of therapeutically treating psychophysiologic diseases and disorders involving neuronal dysregulation. The method additionally provides a pharmacologic composition for the treatment and reduction of drug dependence and which relies upon a combination of an agonist and an antagonist.
REFERENCES:
patent: 2981641 (1961-04-01), O'Neill
patent: 3071509 (1963-01-01), O'Neill
patent: 3980766 (1976-09-01), Shaw et al.
patent: 4597961 (1986-07-01), Etscorn
patent: 4783456 (1988-11-01), Glassman
patent: 4803208 (1989-02-01), Pasternak
patent: 4846199 (1989-07-01), Rose
patent: 4935429 (1990-06-01), Dockis et al.
patent: 5075341 (1991-12-01), Mendelson et al.
patent: 5189064 (1993-02-01), Blum et al.
patent: 5219858 (1993-06-01), Parnell
patent: 5256669 (1993-10-01), Askanaz et al.
patent: 5266574 (1993-11-01), Zagon et al.
patent: 5362496 (1994-11-01), Baker et al.
patent: 5385903 (1995-01-01), Steppuhn et al.
patent: 5403595 (1995-04-01), Kitchell et al.
patent: 5512578 (1996-04-01), Crain et al.
patent: 5556838 (1996-09-01), Mayer et al.
patent: 5565455 (1996-10-01), Bjork et al.
patent: 5574052 (1996-11-01), Rose et al.
Involvement of Cholinergic Nicotine-like Receptors . . . Kurt A Anderson, et al 1982 Acta Physiol Scand. 11G(1). 41-50 Abs.
Behavioral Effects of Intraventricularly Administered Nicotine . . . Victor J. DeNoble, et al., Psychopharmacologia, (Berlin) 77(4), 317-21, 1982.
Nicotine-catecholaminergic Interactions in Rat Brain: . . . Kevin A. Roth, et al., Journal of Pharmacology EXP. THE 221(2), 416-20, 198 abs.
Cardivascular Response in Central Administration of Cholinergic Drugs . . . In Ho Kim, 1981, Ulhakpu Nonmunzip, 34(4) 669-79. Abs.
Interanimal Olfactory aes in Operant Drug Discrimination Procedure K. Extanoc, et al., Psychopharmacology (Berlin) 1981, 73(4), 363-71 abs.
Suppressive Effects of Intraperitoneal and Intraventricular Injections . . . Robert J. Waldhillig Pharmacology, Biochemical Behavior, 12(4), 619-23, 1980 abs.
Nicotine-like Behavioral Effect After Small Doses of Mecamylamine P. Driscoll, Psychopharmacologia, 46(1), 119-21 (1976) abs.
Gawin, FH. Chronic Neuropharmacology of Cocaine: Jr. of Clin. Psychiatry, 49:2 (Feb. 1988), p. 11-16.
Goeders, NE et al. Cortical Dopaminergic Involvement . . . Science, 221 (Aug. 1983) p. 773-775.
Harris, LS. Central Neuropunoral Systems, Fed Proceed ., 20:1 (Jan-Feb 1970), p. 28-32.
Harris, L. et al: Protection Againts Disipropyfluorophosphate Intox., Arch. of Pharm. 1984 327:64-69.
Krystal J., et al. The Intermittent Antagonist Paradigm: Problems of Drug Depend. 1989, p. 45.
Judson, BA, et al. Uses of Naloxone, Research On The Treatment . . . Of The Art. 1983, Chap. 1. p. 1-12.
Meyer, RE, et al. A Behavioral Paradigm, Arch. of General Psych., 33 (Mar. 1976) p. 371-377.
Suzuki, T. et al., Life Sciences, vol. 42(26), pp. 2729-2737 1988.
Comparitive Toxicity For Mice . . . , P. Driscoll. Praeventimedizin 17 (4), 211-213 1972 abstract.
Changes In Body Temperature . . . , G. H. Hall, Br. Jr. of Pharmacology (1972) 44, 634-641.
Temperature Responses In The Rat . . . , J. Baird et al,. European Jr. of Pharmacology 21 (1973) 203-211.
Cardiovascular Responses . . . , British Jr. Pharmac. (1973) 47, 196-205. W.J. Long et al.
Effects Of Nicotine On Self-Stimulation, Pradhan, et al., Jr. of Pharmacology and Experimental Therapeutics 1971, vol. 176, No. 1. p. 229-243.
Titration of Oral nicotine Intake . . . , S.D. Glick, et al. Nature, v. 233, 207-208, 1971.
Nicotine Self-Administration . . . , H.M. Hanson, et al., Ch. 7.
Norman A. Krasnegor, NIDA Research Monograph 23, Jan. 1979. p. 70-9.
Influencing Cigarette Smoking . . . , I.P. Stolerman, et. al., Psychopharmacologia (Berl.) 28-247-249 (1973).
Effects of Mecamylamine On Human Cigarette Smoking . . . , Nemeth-Coslett, et al., Psycho Pharmacology (1986) 88:420-425.
Could Nicotine Antagonists Be Used . . . , by I.P. Stolerman, Br. Jr. of Addiction (1986) 81, 47-53.
Mecamylamine Pretreatment . . . , C.S. Pomerleau, et. al., Psycho Pharmacology (1987) 91:391-393.
Clinical Evaluation of Mecamylamine . . . , F.S. Tennant, Jr., et al., NIDA Research Monograph, 49 (1984). 239-246.
Withdrawal From Nicotine Dependence . . . , F.S. Tennant, Jr., et al., NIDA Research Monograph, 55 (1985). p. 291-297.
Rose, J.E., et al., "Pharm Biochem. & Behavior, " vol. 41 #1, Jan. 1992, p. 219-226.
Levin Edward D.
Rose Jed R.
Sayala Chhaya D.
Schaap Robert J.
Schaap Robert J.
LandOfFree
Agonist-antagonist combination to reduce the use of nicotine and does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Agonist-antagonist combination to reduce the use of nicotine and, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Agonist-antagonist combination to reduce the use of nicotine and will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1120503